S006 Itch
DESCRIPTION
Chronic pruritus, arising idiopathically or in association with cutaneous or systemic disease, may be incapacitating. This session is meant for the clinician who wants to understand how itch arises and how to approach itch management in different clinical scenarios, including but not limited to itch resulting from allergic, systemic, neuropathic and psychogenic disorders. Expert itch clinicians will explain what’s new in itch pathophysiology and will communicate their experience in the diagnosis and management of challenging itches, including neuropathic itch, prurigo nodularis, urticarial and mast cell disorders and psychogenic disorders. Novel and pipeline therapies and devices for the management of chronic itch will be discussed.
LEARNING OBJECTIVES
Categorize different types of chronic itch and utilize appropriate diagnostic tests in the evaluation of patients suffering from chronic pruritus.
Incorporate immunomodulators, neuromodulators and alternative therapies into the management of patients with chronic itch as a manifestation of inflammatory, systemic, or neuropathic or psychiatric disease.
Describe new or pipeline agents to treat chronic itch.
SCHEDULE
9:00 AM
Introduction to the Itch Symposium
Sarina Elmariah, MD, FAAD
9:05 AM
The Clinician's Playbook for Diagnostic Evaluation in Chronic Itch
9:30 AM
Management of Psychogenic Itch Disorders
Rachel E. Meltzer, MD, MPH, FAAD
11:30 AM
Management of itch in pediatric populations
Amy S. Paller, MD, FAAD
DIRECTOR
Sarina Elmariah, MD, FAAD
University of California San Francisco
SPEAKERS
Rachel E. Meltzer, MD, MPH, FAAD
Brigham & Women's Hospital, Harvard Medical School
Amy S. Paller, MD, FAAD
Northwestern University
Sonja Stander, MD, IFAAD
University Hospital Muenster, Germany
DISCLOSURES
Sarina Elmariah, MD, FAAD
Blueprint Medicines – Advisory Board(Honoraria); Celldex – Advisory Board(Honoraria); Disc Medicine – Advisory Board(Honoraria); Galderma Laboratories, LP – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria);
Rachel E. Meltzer, MD, MPH, FAAD
Apogee Therapeutics – Consultant (1099 relationship)(Honoraria), Stockholder Public Company(Stock); Galderma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria); Veradermics – Advisory Board(Honoraria);
Amy S. Paller, MD, FAAD
AbbVie – Data Safety Monitoring Board(Honoraria), Investigator(Grants/Research Funding); Abeona Therapeutics – Data Safety Monitoring Board(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); BioCryst Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Honoraria); BioMendics, LLC – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); Castle Creek Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Chiesi Farmaceutici – Consultant (1099 relationship)(Honoraria); Daiichi Sankyo – Data Safety Monitoring Board(Honoraria); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Galderma – Data Safety Monitoring Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Krystal Biotech, Inc – Consultant(Honoraria); L'Oréal France – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Pelthos Therapeutics – Consultant (1099 relationship)(Honoraria); Quoin Pharmaceuticals Ltd – Consultant (1099 relationship)(Honoraria); Regeneron – Consultant(Honoraria), Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Sonja Stander, MD, IFAAD
AbbVie – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Almirall – Consultant(Honoraria), Investigator(Grants/Research Funding); Beiersdorf, Inc. – Consultant(Honoraria); Bellus Health – Consultant(Honoraria); BMS – Speaker(Honoraria); Cara Therapeutics – Consultant(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria); Galderma – Speaker(Honoraria); Galderma Laboratories, LP – Consultant(Honoraria); Galderma Research & Development, LLC – Consultant(Honoraria); Galderma USA – Investigator(Grants/Research Funding); Incyte – Consultant (1099 relationship)(Honoraria); Kiniksa Pharmaceuticals, Ltd. – Consultant(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Investigator(Grants/Research Funding), Speaker(Honoraria); Novartis – Consultant(Honoraria), Speaker(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sanofi Aventis – Consultant (1099 relationship)(Honoraria); Sanofi Genzyme – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria); UCB – Speaker(Honoraria); University Hospital Muenster – Advisory Board(No Compensation Received); Vifor Pharma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); WebMD – Consultant (1099 relationship)(Honoraria);